E.g., activating death receptor-mediated apoptosis in cancer cells by death ligands (such as TRAIL, FasL and TNFα) is suggested as an effective therapeutic strategy in the treatment of hepatocellular carcinoma [44]; however, this strategy may lead to the induction of apoptosis in adjacent normal hepatocytes and loss of functional tissue. This evidence concerns the gene FASLG and hepatocellular carcinoma.